CD274 Monoclonal Antibody.



Monoclonal antibody of 100 μg targeting CD274 for FCM, IHC.

Target: CD274
Product Type: Antibody
Size: 100 μg
Application: FCM, IHC
Research Area / Disease: Apoptosis
Conjugate: Unlabeled
Antibody Type: Monoclonal
Clone Number: 27A2
Concentration: 1 mg/mL
Formulation: 100 μg IgG in 100 μl volume of PBS containing 50% glycerol, pH 7.2. No preservative iscontained.
Isotype: IgG2b
Immunogen: Recombinant human PD-L1 extracellular domain
Host Species: Mouse
Species Reactivity: Human
Source: This antibody was purified from hybridoma(clone 27A2) supernatant using protein A agarose. Thishybridoma was established by fusion of mouse myelomacell SP2/0 with Balb/c mouse splenocyte immunized withrecombinant human PD-L1 extracellular domain.
Reactivity: This antibody reacts with CD274 antigen on Flow cytometry.
Gene ID Human:


Gene ID Mouse:


Storage Temperature: -20°C
Regulatory Statement: For Research Use Only. Not for use in diagnostic procedures.


  1. Droeser RA et al. Clinical impact of programmed cell death ligand 1 expression in colorectal cancer. Eur J Cancer (2013),
  2. Hamanishi J et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. PNAS. 104, 3360-5 (2007),
  3. Hino R et al. Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer 116, 1757-66 (2010),
  4. Gadiot J et al. Overall survival and PD-L1 expression in metastasized malignant melanoma. Cancer 117, 2192-201 (2011),
  5. Schuchmann M et al. The programmed death (PD)-1/PD-ligand 1 pathway regulates graft-versus-host-reactive CD8 T cells after liver transplantation. Am J Transplant. 8, 2434-44 (2008)